Trend followers stage recovery as stretched S&P, Nasdaq longs fuel gains
Corcept Therapeutics Incorporated (NASDAQ:CORT) has reached an unprecedented milestone as its stock price soared to an all-time high of $71.3. According to InvestingPro data, the company maintains a "GREAT" financial health score and has achieved impressive revenue growth of ~40% over the last twelve months. This remarkable peak reflects a significant surge in investor confidence, propelling the company’s market valuation to $7.4 billion. Over the past year, Corcept has witnessed an extraordinary growth trajectory, with its stock value climbing by over 204%. This surge underscores the biopharmaceutical company’s successful endeavors in developing innovative treatments for severe metabolic, oncologic, and psychiatric disorders. Investors have responded positively to the company’s progress and potential, with analyst price targets reaching as high as $130. InvestingPro analysis suggests the stock is currently trading above its Fair Value, with 15 additional ProTips available for subscribers.
In other recent news, Corcept Therapeutics has been the subject of increased attention from analysts, with H.C. Wainwright and Canaccord Genuity both raising their price targets for the company. H.C. Wainwright lifted its target to $115, citing the potential approval of Corcept’s drug relacorilant as a key driver for future revenue growth. Canaccord Genuity, on the other hand, raised its target to $130, reflecting confidence in the company’s continued clinical and financial progress.
Corcept has also submitted a New Drug Application (NDA) to the FDA for relacorilant, a treatment for hypercortisolism. The application follows positive outcomes from various trials, and if approved, the drug is expected to hit the market in the first quarter of 2026. The approval of relacorilant could significantly boost revenues related to Cushing’s syndrome treatments, which are projected to surge to nearly $824 million by 2030.
In addition to these developments, Corcept’s management has been actively delivering on clinical advancements and revenue growth, setting a positive tone for the future. The company’s focus on Cushing’s syndrome, a hormonal disorder caused by prolonged exposure of the body’s tissues to high levels of the hormone cortisol, has been a particular area of interest for analysts and investors alike. Lastly, Corcept reported promising results from a Phase 3 long-term extension study of relacorilant for the treatment of hypercortisolism, further reinforcing the potential of this drug.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.